Insulin developer Thermalin has raised an undisclosed sum from investors including Sanofi and JSR, and plans to close the round at $17.5m.
Pharmaceutical firm Sanofi has led a tranche of undisclosed size for US-based insulin therapy developer Thermalin as part of a series A round it expects to reach at least $17.5m.
Chemical and life science conglomerate JSR also took part in the round through MBLVC, a VC subsidiary of life science subsidiary MBL Group, as did venture capital firm Green Park and Golf Ventures and undisclosed additional investors.
Founded in 2010, Thermalin is developing new forms of insulin to lower the…